Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Rambam Med-Tech Ltd. is currently prosecuting a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio has 4 pending office actions, reflecting a significant level of ongoing engagement with the patent office. This volume of activity suggests that the company is actively developing a diverse range of intellectual property within the biotech and pharmaceutical sectors.
The data indicates that there are 4 distinct examiners and 3 distinct art units involved in the prosecution. This means that every pending office action is being reviewed by a different examiner, although some examiners share the same art unit. This structure provides a variety of examiner perspectives while maintaining some concentration within specific technical groups at the patent office. The use of 4 distinct examiners requires the company to manage four unique prosecution tracks simultaneously.
SALMON, KATHERINE D is the busiest examiner, with 1 busiest examiner pending office action. Given that there are 4 pending office actions in total, the workload is distributed such that no single examiner has an outsized influence on the portfolio. Practitioners must be prepared to address the specific feedback from each of the 4 distinct examiners to successfully move the 4 pending office actions toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
| MYERS, CARLA J | 1 | 49.3% | +46.1% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
| FERNANDEZ, KATHERINE L | 1 | 58.0% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16835608 | INDUCING WEIGHT LOSS BY APPLICATION OF ENERGY | FERNANDEZ, KATHERINE L | 88d overdue |
| 18538027 | METHOD FOR DETERMINING SUITABILITY TO ANTI-TNF ALPHA THERAPY | SALMON, KATHERINE D | — |
| 18033582 | METHODS OF ASSESSING THE THERAPEUTIC ACTIVITY OF AGENTS FOR THE TREATMENT OF IMMUNE DISORDERS | MYERS, CARLA J | — |
| 18004821 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | AUDET, MAURY A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16835608 | INDUCING WEIGHT LOSS BY APPLICATION OF ENERGY | FERNANDEZ, KATHERINE L | 88d overdue |
| 18538027 | METHOD FOR DETERMINING SUITABILITY TO ANTI-TNF ALPHA THERAPY | SALMON, KATHERINE D | — |
| 18033582 | METHODS OF ASSESSING THE THERAPEUTIC ACTIVITY OF AGENTS FOR THE TREATMENT OF IMMUNE DISORDERS | MYERS, CARLA J | — |
| 18004821 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1654 | 1 |
| 3798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18538027 | METHOD FOR DETERMINING SUITABILITY TO ANTI-TNF ALPHA THERAPY | SALMON, KATHERINE D | 1682 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18033582 | METHODS OF ASSESSING THE THERAPEUTIC ACTIVITY OF AGENTS FOR THE TREATMENT OF IMMUNE DISORDERS | MYERS, CARLA J | 1682 | §101§112 | Non-Final OA | — | Pending | Apr 25, 2023 |
| 18004821 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | AUDET, MAURY A | 1654 | §102§103§112 | Final Rejection | — | Pending | Jan 09, 2023 |
| 16835608 | INDUCING WEIGHT LOSS BY APPLICATION OF ENERGY | FERNANDEZ, KATHERINE L | 3798 | §103§112 | Final Rejection | 88d overdue | Pending | Mar 31, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial